Business Context and Reporting Period
This Form 6-K filing by Celsus Therapeutics PLC (noted as Akari Therapeutics Plc in metadata) is dated February 3, 2014. The filing announces the pricing of a public offering of American Depositary Shares (ADSs) and the subsequent listing of these shares on the NASDAQ Capital Market under the ticker symbol "CLTX."
Key Financial Metrics
- Offering Size: 1,333,333 ADSs initially priced, plus 200,000 additional ADSs via the exercise of the over-allotment option.
- Offering Price: $6.00 per ADS.
- Gross Proceeds: Approximately $9,200,000 (before underwriting discounts, commissions, and offering expenses).
- Liquidity: The filing does not provide specific cash flow, debt, or liquidity metrics beyond the expected proceeds from this offering.
Material Changes
The primary material change is the transition of the Company's ADSs from trading on the OTCQB to the NASDAQ Capital Market. Additionally, the Company has secured approximately $9.2 million in gross capital through the full exercise of the underwriter's over-allotment option.
Guidance, Outlook, and Risks
The offering is expected to close on or about February 5, 2014, subject to customary closing conditions. The filing does not contain specific forward-looking guidance, management commentary on operational outlook, or detailed risk factors beyond the standard closing conditions.
Investor Verification Checklist
- Verify the final closing date of the offering (expected February 5, 2014).
- Confirm the net proceeds after deducting underwriting discounts and offering expenses.
- Review the Company's use of proceeds for the $9.2 million raised.
- Check the current trading status of the "CLTX" ticker on the NASDAQ Capital Market.